ReviewExpert review of clinical pharmacology2021
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence.
Review in Expert review of clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed, 2 syntheses or guidelines pooled it, 291 citations in OpenAlex.
- Safety and efficacy of mesenchymal stem cells in COVID-19 patients: A systematic review and meta-analysis.Immunity, inflammation and disease · 2023Pooled it
- The Prognostic Value of Pentraxin-3 in COVID-19 Patients: A Systematic Review and Meta-Analysis of Mortality Incidence.International journal of molecular sciences · 2023Pooled it
- Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial.Scientific reports · 2024Trial
- Efficacy of low-intensity pulsed ultrasound in the treatment of COVID-19 pneumonia.Ultraschall in der Medizin (Stuttgart, Germany : 1980) · 2023Trial
- Advances in human respiratory organoid models for studying the pathogenesis and intervention strategies of COVID-19.Virologica Sinica · 2026Review
- Fostering Inductive and Deductive Learning in Oral Microbiology and Immunology With a Dual-Role Duel Card Game: Explanatory Sequential Mixed Methods Study.JMIR medical education · 2026Article
- Lingering echoes of SARS-CoV-2: mechanistic insights and management of long COVID syndrome.Inflammopharmacology · 2026Review
- Prolonged Evaluation of COVID-19 Vaccine Effectiveness in Healthcare Workers at a Public Tertiary Hospital: A Retrospective Cohort Study.Revista da Sociedade Brasileira de Medicina Tropical · 2026Article
- Remdesivir in COVID-19: pros and cons.Frontiers in pharmacology · 2026Review
- Integrated Risk Assessment of Tannery Effluents using Multivariate Pollution Indices and Health Metrics in Naraguta, Nigeria.Scientific reports · 2025Article
- Cross-sectional study on the relationship between COVID vaccination and willingness to receive the influenza vaccine in Jeddah.Journal of medicine and life · 2025Article
- Analysis of the Incidence and Severity of Cellulitis During the COVID-19 Pandemic in Japan.The Journal of dermatology · 2025Article
- Low Dose Cyclophospahamide is a Feasable Mobilization Regimen in the Covid-19 Era: A Single Center Study from Türkiye.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Association Between Physical Activity, Sedentary Time, and Quality of Life in Patients with Chagas Disease During COVID-19 Pandemic in Brazil: A Cross-Sectional Study.International journal of environmental research and public health · 2025Article
- Exploring the Association Between Digital Health Literacy and Burnout and Depression Among TV Journalists During the COVID-19 Pandemic in Serbia.Healthcare (Basel, Switzerland) · 2025Article
- Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers of COVID-19 Disease Irrespective of Immunosuppression Status: A Case-Control Retrospective Single-Center Study.Pathogens (Basel, Switzerland) · 2025Article
- Prognostic Accuracy of Nutritional Assessment Tools in Critically-Ill COVID-19 Patients.Journal of clinical medicine · 2025Article
- Differentiation of the Cytokine Profile Modified by SARS-CoV-2 and Influenza Virus in an In Vitro Experiment.Bulletin of experimental biology and medicine · 2025Article
- Fulminant Type 1 Diabetes Mellitus With Concomitant Coxsackievirus B6 Antibody Elevation and RNA-Based COVID-19 Vaccination: A Case Report and Review of the Literature.Clinical case reports · 2025Article
- COVID-19 Infection, Vaccination, and Severe Coronary Artery Disease in Türkiye: A Retrospective Analysis.Anatolian journal of cardiology · 2025Article
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe COVID-19 pandemic has created a public health crisis, infected millions of people, and caused a significant number of deaths. SARS-CoV-2 transmits from person to person through several routes, mainly via respiratory droplets, which makes it difficult to contain its spread into the community. Here, we provide an overview of the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of COVID-19. AREAS COVERED: Direct person-to-person respiratory transmission has rapidly amplified the spread of coronavirus. In the absence of any clinically proven treatment options, the current clinical management of COVID-19 includes symptom management, infection prevention and control measures, optimized supportive care, and intensive care support in severe or critical illness. Developing an effective vaccine is now a leading research priority. Some vaccines have already been approved by the regulatory authorities for the prevention of COVID-19. EXPERT OPINION: General prevention and protection measures regarding the containment and management of the second or third waves are necessary to minimize the risk of infection. Until now, four vaccines reported variable efficacies of between 62-95%, and two of them (Pfizer/BioNTech and Moderna) received FDA emergency use authorization. Equitable access and effective distribution of these vaccines in all countries will save millions of lives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.